🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the effort against increasingly resistant strains of the infection, according to researchers.

A Global Challenge

The sexually transmitted infection are on the rise globally, with figures suggesting more than 82 million new cases annually. Particularly high rates are reported in Africa and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary step in the reality of rising global incidence, the spread of superbugs and the very limited available drugs currently available.”

Public health authorities are deeply concerned about the surge in treatment-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Gain Approval

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in December for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GSK, gained clearance in close succession. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to see it through.

“This authorization signifies a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Clinical Trial Results and Global Access

Based on results released by a major medical journal, zoliflodacin eradicated over nine in ten of cases of the STI. This places it at an comparable level with the typical regimen, which combines a dual-drug approach. The trial enrolled hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the authority to license and sell the drug in numerous developing nations.

Clinicians on the front lines have expressed positive views. The availability of a easy-to-administer therapy such as this is hailed as a "game-changer" for managing the epidemic. This is viewed as crucial to alleviate the strain of the illness for patients and to stop the proliferation of untreatable gonorrhoea around the world.